Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
- New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented
Oslo, September 21 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that further data from its clinical study on the combination of its universal cancer vaccine, UV1, and the PD-1 checkpoint inhibitor, pembrolizumab, will be disclosed in an oral presentation at the 19th International Congress of the Society for Melanoma Research (SMR) on 18 October 2022.
The presenter will be Dr. Yousef Zakharia, Investigator for the UV1-103 clinical trial. Dr. Zakharia is a Medical Oncologist, Clinical Associate Professor and Director Phase I Program at University of Iowa Hospital and Clinics.
“I am pleased to present the results from the UV1-103 trial to international peers in melanoma research”, said Dr. Yousef Zakharia. Carlos de Sousa, CEO of Ultimovacs added: “As Ultimovacs’ five randomized phase II trials of UV1 continue to mature, there is growing interest in the ability of the vaccine to induce long-lasting, survival-associated immune responses. We are honored to be able to present further data on the clinical activity of UV1.”
Ultimovacs’ presentation is entitled ‘Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Unresectable Melanoma’ and will be given as an oral presentation at the International Congress of the Society for Melanoma Research. Society for Melanoma Research will be online and in-person in Edinburgh, UK, October 17 - 20, 2022. The congress brings together the leaders in the field of basic and translational melanoma research and melanoma clinical trial physicians from around the world.
The presentation will be made available at the Company website on October 18, 2022.
***
About the UV1-103phase I trial in Malignant Melanoma
This US-based Phase I clinical trial is evaluating the Company’s lead candidate, UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first-line treatment in patients with metastatic malignant melanoma. The clinical results for the 30 patients enrolled are:
- Objective response rate (ORR): 57%, complete response rate (CR): 33%
- Median Progression Free Survival (mPFS): 18.9 months (as measured by iRECIST)
- Overall survival after 12 months: 87%, overall survival after 24 months: 73%
Patients will continue to be followed for long-term survival. UV1 has demonstrated a good safety profile, and no unexpected safety issues related to UV1 have been observed in this trial.
The U.S. Food and Drug Administration (FDA) granted a dual Fast Track designation for UV1 in combination with checkpoint inhibitors in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab. Ultimovacs is currently evaluating UV1 as add-on therapy to ipilimumab and nivolumab as first-line treatment for unresectable or metastatic melanoma in a Phase II study named INITIUM.
About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Anne Worsøe, Head of Investor Relations
Email: ir@ultimovacs.com
Phone: +47 906 86 815
Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS26.4.2024 16:20:00 CEST | Press release
Bid procedure, 2024-05-03BondsSWEDISH GOVERNMENT: 1059. SE0007125927. 2026-11-12 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 Bid date2024-05-03Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered volume (corresponding nominal amount)1059: 1000 million SEK +/-1000 million SEK 1063: 900 million SEK +/-900 million SEK Highest permitted bid volume (corresponding nominal amount)1059: 1000 million SEK per bid 1063: 900 million SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2024-05-07Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK Stockholm, 2024-04-26 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and
Press Release on the Filing of a Draft Offer Document Relating to the Simplified Tender Offer For the shares of Believe initiated by Upbeat BidCo SAS26.4.2024 15:20:00 CEST | Press release
PRICE OF THE OFFER: €15 per Believe share DURATION OF THE OFFER: 15 trading days The timetable of the tender offer (the “Offer”) will be set out by the Autorité des marchés financiers (the “AMF”) in accordance with the provisions of its General Regulation. This press release (the “Press Release”) was prepared by Upbeat BidCo and published pursuant to Article 231-16 of the General Regulation of the AMF. The offer and the draft offer document remain subject to review by the AMF. IMPORTANT NOTICE The Press Release must be read together with all other documents published in connection with the Offer. In particular, in accordance with Article 231-28 of the General Regulation of the AMF, a description of the legal, financial and accounting characteristics of Upbeat BidCo will be filed with the AMF and made available to the public no later than the day preceding the opening of the Offer. A press release will be issued to inform the public of the manner in which this information will be made a
The arbitral tribunal has confirmed GF’s redemption right over the minority shares in Uponor and trading in Uponor’s shares has been suspended26.4.2024 15:15:00 CEST | Press release
Uponor Corporation, Stock Exchange Release, April 26, 2024, 4.15 p.m. EET The arbitral tribunal has confirmed GF’s redemption right over the minority shares in Uponor and trading in Uponor’s shares has been suspended The arbitral tribunal appointed by the Redemption Committee of the Finland Chamber of Commerce in connection with the redemption proceedings concerning the minority shares in Uponor Corporation (“Uponor”) has in its interim award confirmed that Georg Fischer AG (“GF”) has the right to redeem the minority shares in Uponor and that GF has the right to obtain title to the minority shares by posting a security approved by the arbitral tribunal for the payment of the redemption price and the possible interest accruing thereon. Uponor announced on March 22, 2024, that Uponor has resolved to apply for the termination of public trading in its shares and for the delisting of its shares from the Official List of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) so that the delisting would occ
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)26.4.2024 15:00:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 26 APRIL 2024 at 16.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 25 April 2024 below five (5) per cent of Orion Corporation’s total shares. Total positions of BlackRock, Inc. and its funds subject to notification: % of shares and voting rights (total of point A)% of shares and voting rights through financial instruments (total of point B)Total of both in % (points A + B)Total number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached Below 5% shares Below 5% voting rights Below 5% shares Below 5% voting rights Below 5% shares Below
Decisions of the Organisational Meeting of Harvia Plc’s Board of Directors26.4.2024 15:00:00 CEST | Press release
STOCK EXCHANGE RELEASE 26 April 2024, at 4.00 p.m. EEST Decisions of the Organisational Meeting of Harvia Plc’s Board of Directors Heiner Olbrich was elected the Chair and Catharina Stackelberg-Hammarén was elected the Vice Chair of the Board of Directors at the Board of Directors’ organisational meeting that took place today after Harvia Plc’s Annual General Meeting. Board of Directors elected from among its members Hille Korhonen (Chair), Anders Holmén and Markus Lengauer as members of the Audit Committee. In addition, Harvia Plc’s Board of Directors decided to establish a Personnel and Remuneration Committee. The Committee’s task is to assist the Board of Directors in issues related to personnel and remuneration. The Board of Directors elected from among its members Heiner Olbrich (Chair), Olli Liitola and Catharina Stackelberg-Hammarén as members of the Personnel and Remuneration Committee. Independence of the members of the Board of Directors The Board of Directors assessed the in